Release Date: 24/03/20 08:18 Summary: CEO's letter to shareholders Price Sensitive: Yes Download Document 362.73KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%